Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Akin Atmaca(Heidelberg University), Christian Schumann(University Hospital Ulm), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), D. Vincente Baz(Hospital Universitario Virgen Macarena), Myung‐Ju Ahn(Sungkyunkwan University), Hidetoshi Hayashi(Kindai University), Y Zhang(Daiichi Sankyo (Germany)), M. Pérol(Centre Léon Bérard), Elena Poddubskaya, Satoru Kitazono(The Cancer Institute Hospital), Isamu Okamoto(Kyushu University Hospital), Richard D. Hall(University of Virginia Health System), Aaron Lisberg(APLA Health), Shunichi Sugawara(Sendai Kousei Hospital), L. Paz-Ares(Hospital Universitario 12 De Octubre), Nicolas Girard(Institut Curie), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes), Ria Cornelissen(Erasmus MC Cancer Institute), Jeff M. Sands(Emory University)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k